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Background
Familial platelet disorder with a predisposition to acute
myelogenous leukaemia (FPD-AML, omim#601399) is
an autosomal dominant disorder that is linked to muta-
tions within the RUNX1 gene. The RUNX1 gene, pre-
sent on 21q22.1, plays a role as a regulatory switch in
both embryonic and adult haemopoietic development.
Heterozygous mutations in RUNX1 are a common fea-
ture in FPD-AML with different prognostic outcomes
reported to be attributable to the location of the muta-
tion within the protein domains.
The Australian Familial Haematological Cancer Study
(AFHCS) currently has 56 Australian families registered
with predispositions to haematological malignancy.
RUNX1 mutations have been found in 11 patients from
3 families diagnosed with AML. This figure is predicted
to be higher if screening occurred when FPD was first
detected.
The IMVS, Adelaide, now offers full RUNX1 gene
screening. To date, we have screened 25 individuals and
confirmed germline mutations in 2 AFHCS families. We
have reported a novel germline heterozygous nonsense
mutation (c.958C>T, p.Arg320X), and a deletion of
exons 2,3 and 4 (c.59-32857_508+2502del).
Recent research is highlighting the role of monoallelic
RUNX1 mutations in the generation and progression of
pre-leukaemic FPD to AML. The evidence suggests that
different prognostic outcomes are dependent on the
impact the mutation has on the final product, although
there is a wide degree of genetic heterogeneity observed.
This has implications for the management and treat-
ment options available to individuals affected. It has also
proved useful in selecting family members negative for
the familial mutation who may be suitable as bone mar-
row donors.
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